Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HK1 | P19367 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782810 | 0.90 | PTGDR2 (0.75) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1784363 | 0.89 | PTGDR2 (0.76) | PTGDR2PTGIRPTGDR | |
| SCHEMBL2670026 | 0.87 | PTGDR2 (0.65) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL2277554 | 0.86 | PTGDR2 (0.75) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL2272115 | 0.86 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL2670014 | 0.86 | PTGDR2 (0.64) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL2670222 | 0.86 | PTGDR2 (0.57) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL2670024 | 0.85 | PTGDR2 (0.62) | PTGDR2ALDH1A1HK1SMN1; SMN2HKDC1 | |
| SCHEMBL3178268 | 0.84 | PTGDR2 (0.62) | PTGDR2SMN1; SMN2 | |
| SCHEMBL2670051 | 0.84 | PTGDR2 (0.49) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168673-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-05-01 | — | — | US | disclosed |
| EP-2240444-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093029-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, NR2C2 | PTGDR2 112/4885ALDH1A1 3417/4885HK1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.